[[["", "", "Final Report", "", ""], ["Patient", "Specimen Information", "Ordered By", "", ""], ["Name: Patient, Test", "Primary Tumor Site: Anterior wall of bladder", "Orrrdddeeerrriiinnnggg   PPPhhhyyysssiiiccciiiaaannn,,,   MMMDDD", "", ""], ["Date of Birth: XX/Mon/19XX", "Specimen Site: Bladder, NOS", "Cancer Center", "", ""], ["", "", "123 Main Street", "", "E."], ["", "", "", "", ""], ["Sex: Female", "Specimen ID: ABC-1234-XYZ", "", "", ""], ["", "", "Springfield, XY 12345, USA", "S", ""], ["Case Number: TN19-XXXXXX", "Specimen Collected: XX-Mon-2019", "", "", ""], ["", "", "1 (123) 456-7890", "", ""], ["Diagnosis:  Sarcomatoid carcinoma", "Completion of Testing: XX-Mon-2019", "", "", ""], ["", "", "", "A L U", ""], ["High Impact Results", "", "", "", ""], ["", "", "R C LINIC", "", ""]], [["", "", "", "", "", "U", "", "", ""], ["Additional Results", "", "", "", "", "", "", "", ""], ["", "C A N C E R   T Y P E   R E L E V A N T   B I O M A R K E R S", "", "", "E P", "", "", "C A N C E R   T Y P E   R E L E V A N T   B I O M A R K E R S   ( c o n t )", ""], ["", "", "", "A TIV", "", "", "", "", ""], ["Biomarker", "Method", "Result", "", "", "", "Biomarker", "Method", "Result"], ["MSI", "NGS", "Stable\nS T R", "", "", "", "FGFR2", "RNA-Seq", "Fusion Not Detected"], ["Mismatch Repair Status", "", "Proficient", "", "", "", "", "NGS", "Mutation Not Detected"], ["", "", "", "", "", "", "FGFR3", "", ""], ["NTRK1", "RNA-Seq", "Fusion Not Detected\nR ILL U", "", "", "", "", "RNA-Seq", "Fusion Not Detected"], ["", "", "", "", "", "", "", "", ""], ["NTRK2", "RNA-Seq", "Fusion Not Detected", "", "", "", "RB1", "NGS", "Mutation Not Detected"], ["NTRK3", "RNA-Seq", "Fusion Not Detected\nR T. F O", "", "", "", "TSC1", "NGS", "Mutation Not Detected"], ["", "", "", "", "", "", "", "", ""], ["Tumor Mutational Burden", "", "High | 19 Mutations/Mb", "", "", "", "", "O T H E R   F I N D I N G S    (see page 2 for additional results)", ""], ["", "O", "", "", "", "", "", "", ""], ["ATM", "NGS", "Mutation Not Detected", "", "", "", "Biomarker", "Method", "Result"], ["", "P", "", "", "", "", "", "", ""], ["", "E", "", "", "", "", "", "", ""], ["ERBB2 (Her2/Neu)", "NGS", "Mutation Not Detected", "", "", "", "", "", "Mutated, Pathogenic"], ["", "", "", "", "", "", "ARID1A", "NGS", ""], ["ERCC2\nP L E R", "NGS", "Mutation Not Detected", "", "", "", "", "", "Exon 3 | p.Q479*"], ["", "", "", "", "", "", "", "", ""], ["", "", "", "", "", "", "", "", ""], ["FANCC\nM", "NGS", "Mutation Not Detected", "", "", "", "", "", "Mutated, Presumed Pathogenic"], ["", "", "", "", "", "", "ERBB3", "NGS", ""], ["A", "", "", "", "", "", "", "", ""], ["FGFR1", "RNA-Seq", "Fusion Not Detected", "", "", "", "", "", "Exon 3 | p.M91I"], ["S", "", "", "", "", "", "", "", ""]], [["", "Final Report", "", ""], ["Biomarker Results", "", "", ""], ["This summary includes biomarkers most commonly associated with cancer. Complete details of all biomarkers tested can be found in the Appendix.", "", "", ""], ["", "", "", "E."], ["", "", "", ""], ["G E N O M I C   S I G N A T U R E S", "", "", "S"], ["Biomarker\nMethod\nResult", "", "A L U", ""], ["", "", "", ""], ["Microsatellite Instability (MSI)\nNGS\nStable", "", "", ""], ["Result: High", "R C LINIC", "", ""], ["Tumor Mutational Burden (TMB)\nNGS", "", "", ""], ["", "", "", ""], ["19", "", "", ""], ["Low\n7\nIntermediate\n17\nHigh", "O", "", ""], ["T F", "", "", ""], ["O", "", "", ""], ["G E N E S   T E S T E D   W I T H   M U T A T I O N S / A L T E R A T I O N S", "", "", ""], ["Gene\nMethod\nVariant Interpretation\nProtein Alteration\nN L Y. N", "DNA Alteration", "", "Variant Frequency %"], ["", "", "", ""], ["", "", "", ""], ["ARID1A\nNGS\nMutated, Pathogenic\np.Q479*\nS O", "c.1435C>T", "", "14"], ["BRCA2\nNGS\nMutated, Variant of Unknown Significance\np.S1667L\n11", "c.5000C>T", "", "15"], ["E", "", "", ""], ["S", "", "", ""], ["ERBB3\nNGS\nMutated, Presumed Pathogenic\np.M91I\n3", "c.273G>A", "", "38"], ["O", "", "", ""], ["P", "", "", ""], ["TP53\nNGS\nMutated, Pathogenic\np.Q331*\n9", "c.991C>T", "", "38"], ["R", "", "", ""], ["U", "", "", ""], ["Transcript ID and Variants of Unknown Significance can be found in the Appendix.", "", "", ""], ["E P", "", "", ""], ["Other Findings\nA TIV", "", "", ""], ["I M M U N O H I S T O C H E M I S T R Y   ( I H C )", "", "", ""], ["S T R", "", "", ""], ["Biomarker\nResult\nBiomarker\nResult", "", "", ""], ["MLH1\nPositive | 2+, 90%\nPD-L1 (22c3)\nR ILL U", "Positive, CPS: 60", "", ""], ["", "", "", ""], ["MSH2\nPositive | 2+, 100%\nPMS2", "Positive | 1+, 100%", "", ""], ["MSH6\nPositive | 2+, 95%", "", "", ""], ["R T. F O", "", "", ""], ["G E N E S   T E S T E D   W I T H O U T   P O I N T   M U T A T I O N S   O R   I N D E L S   B Y   N G S\nO", "", "", ""], ["P", "", "", ""], ["ERBB2\nE", "", "", ""], ["ATM\nBRCA1\nCCND1\nCDKN2A\nEGFR\n(Her2/\nERCC2\nFANCC", "FGFR3", "HRAS", "IDH1"], ["Neu)\nP L E R", "", "", ""], ["", "", "", ""], ["", "", "", ""], ["KIT\nMET\nMTOR\nNRAS\nNTRK1\nNTRK2\nNTRK3\nPDGFRA\nM", "PIK3CA", "RB1", "RET"], ["A", "", "", ""], ["TSC1", "", "", ""], ["S", "", "", ""], ["", "Additional results continued on the next page. >", "", ""], ["PATIENT: Patient, Test (XX-Mon-19XX)\nTN19-XXXXXX", "PHYSICIAN: Ordering Physician, MD", "", ""], ["4610 South 44th Place, Suite 100 \u2022 Phoenix, AZ 85040 \u2022 (888) 979-8669 \u2022 Fax: (866) 479-4925", "", "", ""], ["CLIA 03D1019490 \u2022 CAP 7195577 \u2022 ISO 15189:2012 \u2022 Zoran Gatalica, MD, DSc, Medical Director \u2022 \u00a92019 Caris Life Sciences. All rights reserved.", "", "", "Page 2 of 6"]], [["\u2022", "Biomarker(s): identify specific biomarkers associated with open clinical trials to choose from", "", "", "", "", ""], ["\u2022 Drug(s): search for specific therapies", "", "", "", "", "", "A L U"], ["", "", "", "", "", "", ""], ["\u2022", "Trial Sponsor: locate trials based on the organization supporting the trial(s)", "", "", "", "", ""], ["Visit  www.CarisMolecularIntelligence.com  to view all matched trials. Therapeutic agents listed below may or may not be currently FDA", "", "", "", "", "", ""], ["approved for the tumor type tested.", "", "", "", "", "", "R C LINIC"], ["", "", "", "", "", "", ""], ["", "", "", "", "", "", ""], ["", "", "T A R G E T E D   T H E R A P Y   C L I N I C A L   T R I A L S   ( 2 1 1 )", "", "", "", "O"], ["Drug Class", "Biomarker", "Method", "", "", "", "Investigational Agent(s)"], ["", "", "", "", "", "", "T F"], ["", "", "", "", "", "", ""], ["Akt inhibitors (4)", "ARID1A", "NGS", "", "", "", "ARQ092, AZD5363\nO"], ["Cell cycle inhibitors (3)", "TP53", "NGS", "", "", "", "LY2606368"], ["", "PD-L1", "IHC", "", "", "", "MEDI4736, MK-3475, MPDL3280A, MSB0010718C,\nN L Y. N"], ["Immunomodulatory agents (196)", "", "", "", "", "", "atezolizumab, avelumab, durvalumab, nivolumab,"], ["", "TMB", "NGS", "", "", "", "pembrolizumab"], ["", "", "", "", "", "S O", ""], ["", "", "", "", "", "", ""], ["Pan-HER inhibitors (8)", "ERBB3", "NGS", "", "E", "", "afatinib, lapatinib, neratinib, pyrotinib"], ["", "", "", "S", "", "", ""]], [["", "Final Report", "", ""], ["", "To view the rest of the report, contact a", "", ""], ["", "", "", "E."], ["", "", "", "S"], ["Caris Molecular Intelligence\u00ae", "", "", ""], ["", "", "A L U", ""], ["representative today.", "", "", ""], ["", "R C LINIC", "", ""], ["O", "", "", ""], ["(888) 979- 8669\nT F", "", "", ""], ["O", "", "", ""], ["", "CustomerSupport@carisls.com", "", ""], ["N L Y. N", "", "", ""], ["S O", "", "", ""], ["E", "", "", ""], ["S", "", "", ""], ["O", "", "", ""], ["P", "", "", ""], ["R", "", "", ""], ["U", "", "", ""], ["E P", "", "", ""], ["A TIV", "", "", ""], ["S T R", "", "", ""], ["R ILL U", "", "", ""], ["R T. F O", "", "", ""], ["O", "", "", ""], ["P", "", "", ""], ["E", "", "", ""], ["P L E R", "", "", ""], ["M", "", "", ""], ["A", "", "", ""], ["S", "", "", ""], ["PATIENT: Patient, Test (XX-Mon-19XX)\nTN19-XXXXXX", "PHYSICIAN: Ordering Physician, MD", "", ""], ["4610 South 44th Place, Suite 100 \u2022 Phoenix, AZ 85040 \u2022 (888) 979-8669 \u2022 Fax: (866) 479-4925", "", "", ""], ["CLIA 03D1019490 \u2022 CAP 7195577 \u2022 ISO 15189:2012 \u2022 Zoran Gatalica, MD, DSc, Medical Director \u2022 \u00a92019 Caris Life Sciences. All rights reserved.", "", "", "Page 6 of 6"]]]